One case report described a 5-year-old boy with FIRES treated effectively with emapalumab-Izsg, an IFN-γ neutralizing antibody, after failing treatment with anakinra, tocilizumab, and rituximab and subsequently developed secondary hemophagocytic lymphohistiocytosis (HLH). This evidence concerns the gene IFNG and hemophagocytic syndrome.